Efficacy and Tolerability of an Inhaled Selective Glucocorticoid Receptor Modulator – AZD5423 – in Chronic Obstructive Pulmonary Disease Patients: Phase II Study Results

This study suggests that the selected population of patients with COPD does not respond to treatment with AZD5423 as regards lung function, while showing the expected systemic effects. It cannot be ruled out that a favourable lung function response of AZD5423 can be evoked using another experimental setting and/or within a different population of patients with COPD.

Source: Basic and Clinical Pharmacology and Toxicology - July 17, 2017 Category: Drugs & Pharmacology Authors: Piotr Kuna, Magnus Aurivillius, Carin Jorup, Susanne Prothon, Ziad Taib, Staffan Edsb äcker Tags: Original Article Source Type: research